Crestor's Profile, Price Make It Best Value Among Statins, AstraZeneca Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Crestor is the "most economical option," the company tells investors. Rhabdomyolysis reports hurt the product launch, but AstraZeneca now expects a "strong drive" toward its goal of capturing 20% market share.